“…Despite promising treatment responses, immunotherapy can lead to significant adverse side effects. Moreover, irAEs may be steroid-refractory, necessitating the use of biologics, surgical management, and early treatment discontinuation [ 48 , 49 , 50 , 51 ]. In monotherapy, immune checkpoint inhibitors typically have grade 3 or higher adverse events at an incidence less than 10%.…”